

The December 1, 2020, article by Dimopoulos et al entitled “Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial” (*J Clin Oncol* 10.1200/JCO.20.02060) was published with an error.

The following statement should have been included in the Data Sharing Statement section:

“The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants data supporting

the results reported in this article, will be available three months from initial request to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection and requirements for consent and anonymization.”

This has been corrected as of February 8, 2022. *Journal of Clinical Oncology* apologizes for the error.

**DOI:** <https://doi.org/10.1200/JCO.22.00210>

